We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Inventiva SA (IVA) EUR0.01

Sell:€10.86 Buy:€11.18 Change: €0.1 (0.91%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: €0.1 (0.91%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: €0.1 (0.91%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Contact details

50 rue de Dijon, Daix
+33 (3) 80447500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€449.61 million
Shares in issue:
38.66 million
Euronext Paris

Key personnel

  • Frederic Cren
    Chairman of the Board, Chief Executive Officer, Co-Founder, Member of the Executive Committee
  • Pierre Broqua
    Deputy Chief Executive Officer, Co-Founder, Chief Scientific Officer, Member of the Executive Committee
  • Jean Volatier
    Chief Financial Officer, Chief Administrative Officer, Member of the Executive Committee
  • Nathalie Harroy
    Human Resource Manager, Member of the Management Committee
  • David Nikodem
    Vice President US Operations
  • Susan Coles
    Member of the Executive Committee, Legal Director
  • Michael Cooreman
    Member of the Executive Committee, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.